User Fee Negotiators Far Apart: Industry Seeks To Delay New Fee Levels Until FDA Improves Performance
This article was originally published in The Gray Sheet
Executive Summary
Device industry reps say industry-paid FDA user fees should be reauthorized for only two years, not five, to allow ongoing changes to FDA's pre-market review programs to sink in before a more meaningful user fee package is passed.
You may also be interested in...
CDRH Officials Reveal Top Challenges To Executing User Fee Updates
Hiring and retaining the staff, adjusting the internal culture at CDRH and rebuilding relationships with industry and other public stakeholders are among FDA’s top challenges in meeting the demands of the new device user fee program, according to CDRH Director Jeffrey Shuren.
FDA Wary Of Industry’s New Pre-Market Review Goal Proposals
Recent device industry proposals for more aggressive pre-market review goals could result in fewer device clearances and approvals, FDA warns.
FDA Wary Of Industry’s New Pre-Market Review Goal Proposals
Recent device industry proposals for more aggressive pre-market review goals could result in fewer device clearances and approvals, FDA warns.